TrialJCO precision oncology2025

Geneva Homologous Recombination Deficiency Test Is Predictive of Survival Benefit From Olaparib and Bevacizumab Maintenance in Ovarian Cancer.

Yann Christinat et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.